annamycin

Oncology A liposomal anthracycline for treating CAs–eg multiple-drug-resistant tumors–eg, refractory breast CA, refractory/relapsed AML, ALL, blast crisis of CML. See Anthracycline, Liposomes.

References in periodicals archive ?

M2 PHARMA-March 23, 2017-Moleculin awarded orphan drug designation for Annamycin to treat acute myeloid leukemia

Pharmaceutical company Moleculin Biotech Inc (NasdaqCM:MBRX) reported on Wednesday the receipt of Orphan Drug Designation from the US Food and Drug Administration (FDA) for Annamycin.

The company's lead candidate Annamycin, also known as Liposomal Annamycin, is indicated for the treatment of acute myeloid leukemia (AML).

Annamycin is an anthracycline intended for the treatment of relapsed or refractory AML.

Moleculin awarded orphan drug designation for Annamycin to treat acute myeloid leukemia

M2 EQUITYBITES-March 23, 2017-Moleculin awarded orphan drug designation for Annamycin to treat acute myeloid leukemia

Moleculin awarded orphan drug designation for Annamycin to treat acute myeloid leukemia

Dermin") to use the latter's supply of Annamycin for its proposed clinical trial.

We look forward to beginning our expanded clinical trials on Annamycin by the first half of 2017.

United States : Moleculin Biotech signs Annamycin supply deal with Dermin

Many anti-cancer agents such as doxorubicin, daunorubicin, annamycin, vincristine, paclitaxel and cisplatin, camptothecin and 5-fluorouracil derivatives have been successfully encapsulated in liposomes.

Pharmaceutical particulate carriers: lipid--based carriers

And his early work on Annamycin, a drug that we recently in-licensed from M.

Callisto Pharmaceuticals appoints Dr. Roman Perez-Soler to its scientific advisory board

Full browser ?

CITE

Site: Follow: Share:

Open / Close